KH003(Sailing Pharmaceutical)

Primary objective: To evaluate the safety and tolerability of KH003 in the treatment of advanced solid tumors and provide a safe dosage range for the dosing regimen of later clinical trials. Secondary objectives: 1) To evaluate the pharmacokinetic characteristics of KH003 in patients with advanced solid tumors; 2) To evaluate the anti-tumor efficacy of KH003; 3) To evaluate the immunogenicity of KH003 in patients with advanced solid tumors. Exploratory objective: To evaluate the correlation between biomarkers in patient tumor or blood samples and the efficacy of KH003.